Corbus Pharmaceuticals reposted this
Ian Hodgson is #hiring. Know anyone who might be interested?
Corbus is a precision oncology company committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ internal development pipeline includes CRB-701, a next generation antibody drug conjugate (ADC) that targets the expression of Nectin 4-on cancer cells to release a cytotoxic payload and CRB-601, and anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells. We are tenacious and will keep pushing the known boundaries to make breakthroughs where others have not.
External link for Corbus Pharmaceuticals
500 River Ridge Dr
Norwood, Massachusetts 02062, US
Corbus Pharmaceuticals reposted this
Ian Hodgson is #hiring. Know anyone who might be interested?
Attending the Wedbush PacGrow Healthcare Conference being held August 13-14, 2024? Our CEO Yuval Cohen, Ph.D. will provide a corporate update and participate in one-on-one investor meetings. Details: https://bit.ly/3SpXtQU
Our CEO, Yuval Cohen, Ph.D., highlights the continued progress made across Corbus' pipeline as well as potential upcoming milestones. Read more for key corporate updates: https://bit.ly/3ytrU1B
Corbus today provided a corporate update and reported financial results for the quarter ended June 30, 2024. For details and key corporate updates: https://bit.ly/3ytrU1B
Corbus CEO, Yuval Cohen, Ph.D., will participate in the BTIG Virtual Biotechnology Conference being held August 5-6, 2024. For more info: https://bit.ly/3SpXtQU
Corbus today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in the BTIG Virtual Biotechnology Conference and the Wedbush PacGrow Healthcare Conference during the month of August. Dr. Cohen will provide a corporate update and participate in one-on-one investor meetings at the following events. For details: https://bit.ly/3SpXtQU
Tune-in today, June 12th at 2:40 p.m. ET corporate update from Corbus CEO, Yuval Cohen, Ph.D., at the 45th Annual Goldman Sachs Global Healthcare Conference: https://bit.ly/3R5a1MG
Our CEO Yuval Cohen, Ph.D. will provide a corporate update tomorrow, June 12th at 2:40 p.m. ET at the 45th Annual Goldman Sachs Global Healthcare Conference. For webcast information: https://bit.ly/3R5a1MG
Dr. Dominic Smethurst, Chief Medical Officer at Corbus, comments on the clinical update of SYS6002 (CRB-701), a next-generation Nectin-4 targeting antibody drug conjugate, presented at #ACO24. Read more: https://bit.ly/3wP0oLn
A clinical update presented at #ASCO24 showed that SYS6002 (CRB-701), a next-generation Nectin-4 targeting antibody drug conjugate, continues to demonstrate encouraging safety and efficacy observed in patients with Nectin-4 positive tumors. Learn more: https://bit.ly/3V9UTyM